Remdesivir 用于治疗印度尼西亚 COVID-19 住院患者的安全性结果

Pub Date : 2024-06-03 DOI:10.46542/pe.2024.243.348352
D. Hasmono, Samirah Samirah, R. Hartono, M. Subkhan, Maria Angelia Yoshida, Fenny Kesuma Leliga
{"title":"Remdesivir 用于治疗印度尼西亚 COVID-19 住院患者的安全性结果","authors":"D. Hasmono, Samirah Samirah, R. Hartono, M. Subkhan, Maria Angelia Yoshida, Fenny Kesuma Leliga","doi":"10.46542/pe.2024.243.348352","DOIUrl":null,"url":null,"abstract":"Background: Remdesivir has been granted emergency use authorisation for hospitalised COVID-19 patients. However, the available evidence in Indonesia is limited to related liver and kidney injuries.\nObjective: This study aims to assess the safety of remdesivir based on liver and kidney function and its association with comorbidity and disease severity.\nMethod: This retrospective study evaluated remdesivir's efficacy in hospitalised COVID-19 patients of varying severity by collecting baseline and follow-up data on aspartate aminotransferase (AST), alanine aminotransferase (ALT), Glomerular filtration rate (GFR) and Blood urea nitrogen (BUN).\nResult: In this study, 189 patients with elevated transaminase enzyme levels were given hepatoprotection therapy. Patients who did not receive the treatment experienced a significant rise in ALT levels (p < 0.001), while BUN levels increased significantly (p = 0.001) but within the normal range. There was no worsening of GFR value (p < 0.001), and no significant association was found between AST and ALT levels with comorbidity and disease severity (p < 0.001; OR 50.202).\nConclusion: Remdesivir demonstrated good tolerability despite increased ALT and BUN without correlating to comorbidity or disease severity in COVID-19.","PeriodicalId":0,"journal":{"name":"","volume":"5 6","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Safety outcomes of remdesivir for treatment of COVID-19 hospitalised patients in Indonesia\",\"authors\":\"D. Hasmono, Samirah Samirah, R. Hartono, M. Subkhan, Maria Angelia Yoshida, Fenny Kesuma Leliga\",\"doi\":\"10.46542/pe.2024.243.348352\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: Remdesivir has been granted emergency use authorisation for hospitalised COVID-19 patients. However, the available evidence in Indonesia is limited to related liver and kidney injuries.\\nObjective: This study aims to assess the safety of remdesivir based on liver and kidney function and its association with comorbidity and disease severity.\\nMethod: This retrospective study evaluated remdesivir's efficacy in hospitalised COVID-19 patients of varying severity by collecting baseline and follow-up data on aspartate aminotransferase (AST), alanine aminotransferase (ALT), Glomerular filtration rate (GFR) and Blood urea nitrogen (BUN).\\nResult: In this study, 189 patients with elevated transaminase enzyme levels were given hepatoprotection therapy. Patients who did not receive the treatment experienced a significant rise in ALT levels (p < 0.001), while BUN levels increased significantly (p = 0.001) but within the normal range. There was no worsening of GFR value (p < 0.001), and no significant association was found between AST and ALT levels with comorbidity and disease severity (p < 0.001; OR 50.202).\\nConclusion: Remdesivir demonstrated good tolerability despite increased ALT and BUN without correlating to comorbidity or disease severity in COVID-19.\",\"PeriodicalId\":0,\"journal\":{\"name\":\"\",\"volume\":\"5 6\",\"pages\":\"\"},\"PeriodicalIF\":0.0,\"publicationDate\":\"2024-06-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.46542/pe.2024.243.348352\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.46542/pe.2024.243.348352","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

背景介绍雷米替韦已获准紧急用于住院的 COVID-19 患者。然而,印尼现有的证据仅限于相关的肝脏和肾脏损伤:本研究旨在根据肝肾功能及其与合并症和疾病严重程度的关系评估雷米替韦的安全性:这项回顾性研究通过收集天冬氨酸氨基转移酶(AST)、丙氨酸氨基转移酶(ALT)、肾小球滤过率(GFR)和血尿素氮(BUN)的基线和随访数据,评估雷米替韦对不同严重程度的住院COVID-19患者的疗效:在这项研究中,189 名转氨酶水平升高的患者接受了保肝治疗。未接受治疗的患者的谷丙转氨酶水平显著升高(p < 0.001),而血尿素氮水平显著升高(p = 0.001),但在正常范围内。GFR值没有恶化(p < 0.001),AST和ALT水平与合并症和疾病严重程度无明显关联(p < 0.001; OR 50.202):结论:在COVID-19研究中,尽管ALT和BUN升高,但雷米替韦显示出良好的耐受性,且与合并症或疾病严重程度无关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
分享
查看原文
Safety outcomes of remdesivir for treatment of COVID-19 hospitalised patients in Indonesia
Background: Remdesivir has been granted emergency use authorisation for hospitalised COVID-19 patients. However, the available evidence in Indonesia is limited to related liver and kidney injuries. Objective: This study aims to assess the safety of remdesivir based on liver and kidney function and its association with comorbidity and disease severity. Method: This retrospective study evaluated remdesivir's efficacy in hospitalised COVID-19 patients of varying severity by collecting baseline and follow-up data on aspartate aminotransferase (AST), alanine aminotransferase (ALT), Glomerular filtration rate (GFR) and Blood urea nitrogen (BUN). Result: In this study, 189 patients with elevated transaminase enzyme levels were given hepatoprotection therapy. Patients who did not receive the treatment experienced a significant rise in ALT levels (p < 0.001), while BUN levels increased significantly (p = 0.001) but within the normal range. There was no worsening of GFR value (p < 0.001), and no significant association was found between AST and ALT levels with comorbidity and disease severity (p < 0.001; OR 50.202). Conclusion: Remdesivir demonstrated good tolerability despite increased ALT and BUN without correlating to comorbidity or disease severity in COVID-19.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信